Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-WORTHy: Grazoprevir and Elbasvir in Chronic Hepatitis C
NCT01717326Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of grazoprevir, elbasvir in hepatitis C (HCV), sponsored by Merck & Co.. Started Feb 2013; status: completed.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01717326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01717326.